Galmed Pharmaceuticals Ltd. - ADR
$4.12
$-0.05
(-1.08%)
As on 31-Aug-2026 16:00EDT
Market cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-11.7
-
Face value
--
-
Shares outstanding
1,041,565
10 Years Aggregate
CFO
$-149.69 Mln
EBITDA
$-169.08 Mln
Net Profit
$-162.42 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Galmed Pharmaceuticals - ADR
| -31.4 | -14.0 | -31.7 | -59.4 | -62.4 | -75.6 | -51.3 |
|
BSE Sensex*
| -8.9 | -1.2 | 3.2 | -3.3 | 6.0 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Galmed Pharmaceuticals - ADR
| -76.5 | -93.9 | -72.5 | -41.5 | -46.2 | -15.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Galmed Pharmaceuticals - ADR
|
4.1 | 4.3 | 0.0 | -13.4 | -- | -90.4 | -- | 0.3 |
| 2.6 | 246.3 | 74.0 | 35.2 | 0.0 | 36.8 | 6.8 | 2.9 | |
| 0.5 | 8.7 | 1.3 | -9.1 | -1,029.8 | -- | -- | 6.2 | |
| 69.1 | 225.3 | 1.8 | -16.3 | 0.0 | -46.1 | -- | 4.9 | |
| 43.1 | 2,132.2 | 188.7 | -97.6 | -38.6 | -- | -- | 19.3 |
Shareholding Pattern
View DetailsAbout Galmed Pharmaceuticals - ADR
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate... molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. Read more
-
Co-Founder, President, CEO & Chairman
Mr. Allen Baharaff
-
Co-Founder, President, CEO & Chairman
Mr. Allen Baharaff
-
Headquarters
Ramat Gan
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Galmed Pharmaceuticals - ADR
What is the current share price of Galmed Pharmaceuticals Ltd - ADR Today?
The share price of Galmed Pharmaceuticals Ltd - ADR is $4.12 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Galmed Pharmaceuticals Ltd - ADR has given a return of -62.44% in the last 3 years.
What is the current PB & PE ratio of Galmed Pharmaceuticals Ltd - ADR?
Since, TTM earnings of Galmed Pharmaceuticals Ltd - ADR is negative, P/E ratio is not available.
The P/B ratio of Galmed Pharmaceuticals Ltd - ADR is 0.32 times as on 28-Aug-2026, a 94 discount to its peers’ median range of 4.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.48 |
0.31 |
2024 |
-0.71 |
0.33 |
2023 |
-0.03 |
0.01 |
2022 |
-0.01 |
0.01 |
2021 |
-1.41 |
1.50 |
What is the 52 Week High and Low of Galmed Pharmaceuticals Ltd - ADR?
The 52-week high and low of Galmed Pharmaceuticals Ltd - ADR are Rs 13.20 and Rs 3.29 as of 01-Sep-2026.
What is the market cap of Galmed Pharmaceuticals Ltd - ADR?
Galmed Pharmaceuticals Ltd - ADR has a market capitalisation of $ 4 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Galmed Pharmaceuticals Ltd - ADR?
Before investing in Galmed Pharmaceuticals Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.